Search Bar & Filters
Found 237 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are evaluating whether 18F-choline positron-emission-tomography computed tomography 18F-ch-PET-CT is better than conventional imaging methods like ultrasonography and sestamibi scintigraphy at locating diseased parathyroid glands in adults with primary hyperparathyroidism pHPT. The study aims to improve surgical precision, increase cure rates, reduce complications, and shorten operation times. Primary hyperparathyroidism causes problems like kidney stones and bone weakness because of enlarged parathyroid glands producing too much hormone. This open, randomized clinical trial compares two imaging approaches before surgery. One group receives 18F-ch-PET-CT imaging, while the other undergoes standard ultrasonography and sestamibi scintigraphy. Patients are randomly assigned to one of these groups. The study will measure how long the surgery takes and look at cure rates, complication rates, and the accuracy of each imaging method. The trial is conducted at a single center and does not involve blinding. Participants will have their imaging results and surgery details recorded. Researchers will monitor operation times from start to finish and evaluate cure by checking calcium levels one month after surgery. They will also track complications like nerve damage or persistent disease. Data are collected securely in a national registry. The study aims to include 100 participants and expects to complete analyses within a few years. Safety monitoring includes assessment of potential side effects from the imaging agents used.
Actively Recruiting
Researchers are investigating heart damage caused by certain cancer treatments, such as anthracycline chemotherapy and HER2-targeted therapy, which can affect the hearts function. The study aims to compare a newer heart ultrasound technique called three-dimensional speckle-tracking echocardiography 3D strain with the standard two-dimensional 2D method to see if it detects early heart damage better. This research focuses on adults with breast cancer, lymphoma, or sarcoma undergoing these cancer treatments at Skne University Hospital in Sweden. Participants receive heart ultrasounds, ECGs, and blood tests for heart-related biomarkers before, during, and after their cancer treatment. Those with breast cancer typically have heart imaging every 3 to 4 months, while those with lymphoma or sarcoma have imaging at baseline, 6 months, and 24 months after starting treatment. Blood samples are also collected and stored for future research. Some participants showing signs of heart damage, along with matched controls, may be invited for detailed heart MRI scans. Throughout the study, researchers track changes in heart function using both 3D and 2D ultrasound measures, along with blood biomarkers. They record heart failure medication starts, hospitalizations, and overall survival from health records. This observational study does not alter clinical care, and the imaging results from 3D strain are analyzed separately. Participation involves regular heart assessments over up to 24 months depending on the cancer type.
Actively Recruiting
Researchers are evaluating Flexilev, a Parkinsons disease medicine made of small dissolvable tablets containing low doses of levodopa and carbidopa. The study focuses on how well patients accept and stick with this treatment when delivered using the OraFID dosing device, which accurately dispenses the right number of tablets, and the optional Levilog app that reminds patients to take their doses and records usage. This is an open-label, phase 4 study involving patients with idiopathic Parkinsons disease that responds to levodopa. Participants first undergo a run-in period of up to two weeks where their current treatment is recorded and eligibility is assessed. Eligible patients then switch to Flexilev delivered via the OraFID device and receive individualized dosing based on their doctors evaluation. Other daytime levodopa medications are stopped, though slow-release levodopa at night is allowed. After starting treatment, patients receive follow-up phone calls at weeks 1, 4, and 8, and an in-person visit at week 12, with dose adjustments allowed as needed during the 12-week treatment period. During the study, participants acceptability and satisfaction with the OraFID device and the Levilog app are assessed through questionnaires. Researchers also monitor treatment compliance, safety, changes in motor and non-motor symptoms, depression, quality of life, sleep quality, and disease severity. The total participation lasts up to 12 weeks after the run-in period, with regular phone and in-person assessments to track treatment experience and effects.
Actively Recruiting
Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.
Actively Recruiting
Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.
Actively Recruiting
Researchers are investigating treatments for people with small, unnoticed brain injuries called Covert Brain Infarcts CBIs, which are often found by chance during MRI scans. CBIs do not cause symptoms initially but are linked to higher risks of stroke and death. The study aims to see if medications that prevent stroke, like blood thinners and cholesterol-lowering drugs, can help reduce these risks and whether CBIs increase the chance of dementia. Participants will be randomly assigned to one of four groups one receiving a platelet inhibitor either Aspirin or Clopidogrel without statins, one receiving statin therapy Atorvastatin or Rosuvastatin without platelet inhibitors, one receiving both treatments, and one receiving neither treatment following current prevention guidelines. All groups will receive advice on lifestyle improvements and blood pressure management. Medication doses are carefully adjusted for tolerance, and the study follows a pragmatic, multicenter design. During the study, participants will be monitored for major cardiovascular and brain-related events, bleeding risks, dementia development, cognitive decline, and quality of life over 12 and 36 months. Assessments include MRI scans, physical activity levels, and various scales measuring daily living abilities, frailty, and neurological function. Researchers will also track serious adverse events and subtype characteristics of CBIs. The study duration spans at least three years with regular follow-ups to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating a new non-invasive monitoring system developed by Acorai to estimate intracardiac hemodynamic parameters in patients with suspected or confirmed heart failure andor pulmonary hypertension who require hemodynamic assessment. This observational study aims to collect data to train machine learning models retrospectively, supporting standard clinical assessments by healthcare professionals for personalized treatment. Participants are patients undergoing a right heart catheterization procedure as part of their usual care. Data collection involves a supervised session lasting about 25 minutes before the catheterization, including patient information entry and sensor recording. There is no active treatment or follow-up required beyond standard care, but a single observational follow-up at 90 days will gather data on unplanned hospitalizations. During the study, participants will undergo the data collection session at baseline and will be observed for up to 90 days to evaluate the machine learning models performance in estimating pressure. Researchers will monitor hospitalization events but will not require additional procedures beyond standard medical care. The total study participation spans from the initial session through the 90-day observational period.
Actively Recruiting
Researchers are investigating ways to personalize treatment for patients with head and neck squamous cell carcinoma HNSCC, especially those with advanced disease who face a higher risk of treatment failure. This phase III study compares two radiotherapy approaches for patients intended for curative treatment the standard radiotherapy and a hyperfractionated radiotherapy HFX-RT with a higher total radiation dose. The study also aims to improve prognostic and predictive methods by including exploratory analyses such as MRI to evaluate tumor hypoxia, gene profiling, immune profiling, and imaging texture analyses during treatment and follow-up. Participants will be randomly assigned to either standard radiotherapy, which delivers 68.0 Gy in daily fractions of 2.0 Gy, or to hyperfractionated radiotherapy, which delivers 83.0 Gy in smaller doses twice daily 1.22 Gy per fraction over five days per week. The doses vary depending on the tumor volume and lymph node involvement. Patients with lower-risk tumors not eligible for randomization may still participate in the translational research parts of the study. During the study, participants will be closely monitored with regular follow-up visits every three months for two years, then every six months up to five years, focusing on local tumor control. Researchers will collect imaging data, conduct gene and protein analyses, and assess tumor response. The study evaluates treatment effects and tumor behavior over time to better understand and improve outcomes for head and neck cancer patients.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a behavioural intervention called Light, activity and sleep in my daily life LAS aimed at improving quality of life for community-dwelling older adults aged 70 and over. The study focuses on addressing challenges related to circadian rhythm sleep disorders, poor sleep, reduced physical activity, and time spent indoors, which affect wellbeing in this population. The intervention targets light-related behaviour, outdoor walking, and sleep routines to promote active ageing and independence. The LAS intervention is delivered as a 9-week web-based course with nine modules covering electric lighting, daylight, outdoor physical activity, and sleep. Participants also receive a test kit with items like light bulbs, a sleep mask, and a sleep diary to support engagement and experimentation. The course includes one introductory physical meeting and three additional meetings held at a senior citizen meeting point. All participants receive the same noninvasive behavioural education and support. Participants complete questionnaires, interviews, and wear accelerometers to track activity and rest patterns before and after the course, with follow-ups at 3, 6, and 10 months after baseline. Outcomes measured include usability of the intervention, mood, sleep quality, behavioural skills, quality of life, physical activity, sedentary behaviour, and step counts. The study also explores factors that help or hinder daytime outdoor walking. Results will guide improvements for future delivery within municipal health promotion services.
1-10 of 237
1